How Opioid Addiction Alters Our Brains To Always Want More

At a hearing on Capitol Hill earlier this year, U.S. Senator Lamar Alexander asked an important question: Why are most of the treatment for opioid addiction more opioids?

In response, Nora Volkow, director of the National Institute on Drug Abuse, and Walter Koroshetz, director of the National Institute of Neurological Disorders and Stroke, did their best to assure the senator – and thus the nation – that scientists are hard at work developing treatments for addicts that are not just more of the same.

Hacking the Human Brain

The hopeful news regarding the opioid crisis is that scientists are searching for promising targets in developing non-opioid treatments for addiction. For example, this year a Food and Drug Administration advisory committee voted to approve the high blood pressure medicine lofexidine as the first non-opioid medication to treat opioid withdrawal symptoms.

Earlier this year, the NIH launched an initiative called Helping to End Addiction Long-term (HEAL) that takes an important step forward in doing just that. It funds research into potential new treatments aimed at the brain reward pathway – the regions of the brain where neurons release the neurotransmitter dopamine, which gives you a jolt of pleasure, makes you feel good and signals you to repeat this pleasurable behavior in the future.

Continue Reading at The Conversation

Health Summit On Opioid Crisis Held

SPRINGFIELD, Ill. (WAND) – More than 150 people gathered Wednesday for a conference on the Opioid Crisis.

The event called “Opioid Crisis Next Door” included speakers addressing challenges to treating opioid abuse, the experience of people in treatment, Naloxone use, coalition-building and other matters.

“It’s about all of us coming together,” said Pat Schou, executive director of the Illinois Critical Access Hospital Network. “Coalitions shouldn’t just be healthy people or public health people or the coroner or police officers or legal. It’s about everybody together.”

National speaker psychiatrist Dr. Omar Manejwala described the opioid crisis as a “wicked problem”: lacking a definitive definition and a stopping rule that shows when a solution has been found.

Wand 17

London’s First Marijuana Producer Ready To Grow

London’s first licences cannabis producer is gearing up for a major expansion.

INDIVA is holding a private open house on Wednesday to kick off the expansion of its facility in a south London industrial park.

INDIVA spokesperson Susan Mutterback said the company is focused on the medical cannabis market but can expand to include the recreational marijuana market when it becomes legal.

Niel Marotta, the CEO of the publicly traded company, is based in Ottawa but Pete Young, the master grower, is based in London and was a director of the London Compassion Society, which has been providing medicinal marijuana to its carefully screened members since 1995.

At full capacity, INDIVA expects the London facility to produce more than three million grams of high-quality dry flower annually using the latest hydroponic growing systems and LED lighting. The plant will also be able to process more than 1,000 kilograms of cannabis oil. The expansion is expected to be completed later this year. Full production capacity should be reached in 2019.

The London Free Press

What Ever Happened to Denver’s Magic Mushroom Initiative?

Nearly three months ago, a group of Denverites made a big splash with their campaign to decriminalize magic mushrooms, chanting “free the spores” and holding up signs that read, “I am a psilocybin patient,” outside of the Denver City and County Building.

They vowed to turn Denver into a safe space for psychedelics users and, they said, private research. After all, Denver has a history of progressive drug policies; it decriminalized possession of cannabis in 2005, years before statewide recreational legalization.

But the campaign Denver for Psilocybin — backed by members of the cannabis community such as weed doctor and neuroscientist Michele Ross and Straight Hemp CEO Devin Alvarez — has faced hurdles in its bid for the ballot since making its bold announcement in early March. It’s still struggling to get its petition language approved and has been denied twice by the city, most recently on May 7. With little time left to gather signatures before the August deadline, there’s a chance that Denver residents may not see the initiative this November.

Even if Denver for Psilocybin has its petition approved on the third attempt, it would be on a huge time crunch to turn in the requisite 4,726 valid signatures in a little more than a month.

Read the full article at Westword

Some Good News From The Fight Against Opioids

SOME 382,000 Americans have overdosed on opioids—a group of drugs that includes prescription painkillers, heroin and synthetics—since the year 2000. That is greater than the number of American combat deaths in the second world war and the Korean and Vietnam wars combined. Despite this epic toll, there are early signs that at least one battle may be ending.

The Centres for Disease Control and Prevention (CDC) provide the best data for tracking the opioid epidemic. Its latest data, which cover the 12 months to the end of October 2017, show that opioids were responsible for some 46,041 deaths (see chart) in that period. While provisional and subject to revision, that number was at least not dissimilar to the previous month’s figure of 46,202.

The precise workings of the epidemic in recent months are not well understood, but a few elements stand out. The first is that deaths from prescription medication are likely to have been pushed down by lower availability of those drugs. Official data from the CDC show that prescription rates were nearly 20% lower in 2016 than at their 2012 peak. IQVIA, a health consultancy, reckons that prescriptions fell by another 10% in 2017. Donald Burke, dean of the University of Pittsburgh’s graduate school of public health, thinks there is “almost certainly cause and effect” between prescription rates and deaths.

Experts agree that the most effective way to fight addiction is with medication-based treatment, such as methadone. But just one-third of Americans live in counties with treatment centers providing these kinds of drugs. For real progress it is necessary to look north. Vancouver has pioneered the use of safe-injection sites. Seattle and other progressive enclaves of America would like to follow their lead but they face stern opposition. America’s attorney-general, Jeff Sessions, has threatened to prosecute such sites under the “crack house statute”. Such sites, claims the Department of Justice, will only “encourage and normalize heroin use”.

The Economist

Forget Protein Shakes. The Newest Workout Supplement? Marijuana.

Like many other fitness-minded young professionals, a 25-year-old Boston resident named Cameron adheres to a fairly typical pre-workout routine. There’s the 20 minutes of stretching, generally followed by some light cardio.

As marijuana legalization has pushed the drug further toward the mainstream — and a longstanding social stigma has begun to dissipate — more individuals are taking up before hitting the weight room, sports field, or mixed martial arts mat.

While the idea might seem inherently counterintuitive — weed, after all, is a substance more commonly paired with Doritos than deadlifts — there is a passionate contingent that swears by it.

“It’s a weird phenomenon, but it’s an increasingly common phenomenon,” says Peter Grinspoon, a primary care doctor at Massachusetts General Hospital and author of the book “Free Refills: A Doctor Confronts His Addiction.” “The fact that a lot of people are saying it helps them can’t be ignored.”

Research into marijuana’s benefits has been notoriously scant, due in large part to the drug’s federal classification as a Schedule 1 substance — meaning that, along with heroin, LSD, and ecstasy, it’s deemed to have “no currently accepted medical use and a high potential for abuse.” And the few studies that do exist offer relatively little insight into the drug’s effects during physical activity, beneficial or detrimental.

Read the full article at Boston Globe

New Migraine Drug: A Neurologist Explains How It Works

Migraine typically runs in families, with about 90 percent of people with migraine having close relatives with this disorder. It affects 1 of every 7 adults in the U.S. It is three times more common in women than men.

That doesn’t tell the whole story, though. According to the research group Global Burden of Disease, migraine was ranked the sixth most disabling disease. What is more, among neurological disorders, migraine is the second most disabling after stroke.

The FDA announced approval on May 17 of a novel preventive treatment for migraine headaches. Aimovig is the first in a new class of migraine-specific drugs that works by blocking an action of a protein that is increased in people with migraine during headache attacks.

If over-the-counter medications are not effective, a class of drugs called triptans can be very effective. Triptans, the first drugs developed specifically for migraines, were developed in the 1980s and have remained the best option for treatment of individual migraine attacks. Triptans are not pain killers but rather work through serotonin receptors involved in the development of migraine.

Triptans can also cause medication overuse headache. And, they have the potential to cause the spasm of blood vessels. Therefore, triptans should not be used if a person has had a heart attack, stroke or peripheral vascular disease.

Read more at The Conversation

Myanmar Embraces Silkworms Over Poppies

Zhou Xing Ci’s family have farmed poppies for as long as anyone remembers, scraping the flowers’ sticky brown sap to produce opium.

Along with many other farmers in the hills of eastern Myanmar, the crop – much of which ends up as heroin sold on foreign streets – has in recent years put Myanmar behind only Afghanistan as the world’s leading source of opium.

A Chinese company working with farmers like Zhou hopes the silk-producing larva can help the farmers, and their country, quit the drug.

“Growing opium is too tough. It’s only one harvest every year and a rain can easily destroy a whole year’s work,” said Zhou.

The UN agency has assisted more than 1,000 farmers to switch from opium to another cash crop, coffee, since 2014, said Troels Vester, UNODC country manager for Myanmar.

Still, 41,000 hectares of poppy was planted in Myanmar last year, the agency said. Farmers in conflict areas were less likely to have moved to licit crops, it added.

In the corner of Myanmar where Zhou lives, bordering China’s Yunnan province, various armed groups operate and the law is barely enforced, providing a haven for opium traders, as well as heroin producers and meth-lab operators.

Read more at News.com

Time To Tax Narcotics As War On Drugs Will Never Be Won

The war on drugs was lost the moment it started but it continues relentlessly, morphing into a narrative favored by dystopian novelists.

One of the growth areas of academic finance in recent years has resulted in psychologists winning Nobel prizes for economics. The ways in which we are different to the rational, utility-maximising caricature of the textbooks has been usefully explored by researchers and has yielded a stream of insights that have guided policymakers in many jurisdictions.

Researchers are fond of finding weird anomalies in human behaviour that conflict with standard predictions, coming up with theories about why we behave in this way and then suggesting policy “nudges” that lead to better outcomes for both individuals and societies.

Each year, drug use rises. The range and availability of drugs rise. Terrorists rely on valuable income from drugs. The United Nations estimates that up to 85 per cent of Afghanistan’s poppy cultivation is under the control of the Taliban, with half of its income coming from heroin – and most of the world’s supply of that drug is from those fields. Even waging actual war doesn’t work.

In the UK, the Royal College of Physicians, the Faculty of Public Health and the Royal Society for Public Health have joined the calls for decriminalization. All these bodies are keen to stress that they do not condone drug taking but have just looked at the facts and concluded that the current legal framework is not fit for purpose. It simply doesn’t work: drug use is not deterred. Drug users need education and treatment, not legal sanction.

Continue Reading at Irish Times

Things That Matter about Psychoactive Drugs

Psychoactive drugs chemically alter the brain and change the way we feel, think, perceive and understand our world.

We are in a psychoactive drug epidemic in our country, most notably the opioids, because of their tragic death toll.

Here are nine things that matter when it comes to drugs:

1. Age. It’s one thing to start drinking or smoking dope when you are 21. It is very different when at 12 or 13 or 15, even 18.

2. Set. Set means the unique biological, neurological, psychological and experiential qualities of the user. Set creates a personal vulnerability and selective responsivity do substances.

3. Route of Administration. How fast a substance gets to and bathes our neurons with its receptor-loving chemical configuration makes a big difference.

Continue Reading at Scientific America

Some Businesses Stop Drug Testing For Marijuana

A low unemployment rate and the spreading legalization of marijuana have led many businesses to rethink their drug testing policies for the first time in decades. A small but increasing number are simply no longer testing for pot.

“There is a lot of conflict there, and many employers, they just don’t know what to do,” said Kathryn Russo, a lawyer at Melville, New York-based firm Jackson Lewis. Recreational marijuana use is legal in nine states plus Washington, D.C., and medical marijuana is legal in 29 states.

Here are some questions small businesses need to consider when deciding on what drug testing policies to follow:

– IS IT A FEDERALLY REGULATED POSITION, OR SAFETY-SENSITIVE?

If your business is regulated by the federal Department of Transportation or is a defense contractor, you are likely legally required to drug test for all drugs illegal at the federal level, including marijuana.

– DON’T DISCRIMINATE

In states where medical marijuana is legal, small businesses increasingly risk running into legal trouble if they deny a job to someone who has obtained a medical marijuana prescription.

Read more at Eyewitness News

Trump Wants A New War On Drugs

President Trump’s opioid response plan might have multiple prongs, but when he unveiled it Monday, he clearly was most interested in the prong that gets “very tough” on drug dealers. We know this because he said so approximately 5,000 times during a speech announcing the new plan in New Hampshire, a state chosen as the backdrop because it is one of those hardest hit by opioid addiction and overdose deaths.

Trump’s get-tough approach is little more than a reboot of the failed “War on Drugs” from the 1980s, in which the federal government spent enormous sums trying — and failing — to stop the crack cocaine crisis by throwing people in prison, a disproportionate amount of whom were African American and Latino.

His first speech on the topic in October, while vague, promised action on this “public health emergency.” A few days later the commission he convened to study the problem and come up with evidence-based solutions released a 131-page report with 56 recommendations, none of which suggested killing people.

Read the full article in Los Angeles Times

Research Says: Magic Mushroom Could Lead To Help For Addicts

“Getting drugs to the brain can be so difficult, but fungi have already figured out how to do that,” said Hannah Reynolds, assistant professor of biology at Western Connecticut State University and co-author of the new study.

Magic mushrooms owe their mind-bending properties to the production of psilocybin, a brain-altering compound that mimics the neurotransmitter serotonin.

In 1970, national laws swept psilocybin into the category of banned Schedule I drugs, which also includes other psychoactive substances such as LSD, ecstasy (MDMA) and marijuana. Federal restrictions also extended to the use psilocybin in laboratories and clinical trials, which meant that for decades researchers have had extremely limited opportunity to explore its therapeutic potential.

But science is on the cusp of a psychedelic research renaissance, Slot said.

“It’s been a sea change,” he said.

Understanding what environmental conditions cause the natural evolution of mind-altering substances such as psilocybin opens up the possibility of discovering more of them and harnessing them for human use, she said.

Continue Reading at The Alliance Review

Magic Mushrooms Kill the Appetite

New research on the evolutionary genetics of fungi reveals that the compound that makes some mushrooms ‘magic’ may have evolved as a defensive mechanism to discourage invertebrates from eating them.

Psilocybin occurs in a diverse group of fungi, with genetic analysis indicating that it may have evolved several times. This led a group of researchers from the Ohio State University in the US to suspect that a mechanism known as horizontal gene transfer may be occurring.

Horizontal gene transfer involves the movement of genetic material between species, carried by mobile cells such as bacteriophages. It is a process associated with stressful environments, and is rare in complex multicellular organisms.

Researchers found that distantly related fungi in dung and decaying-wood niches showed less variation in their genome content than close relatives in alternative niches. This suggest that the genomes are shaped in part by shared ecological pressures.

It appears that the biological niche of the psilocybin-containing mushrooms provides a clue. In humans, psilocybin causes profound altered states of consciousness and other symptoms such as increased heart rate and dilated pupils.

Read more at Cosmos Magazine

Reason ‘Magic’ Mushrooms Evolved to Get You High

“Magic” mushrooms seem to have passed their genes for mind-altering substances around among distant species as a survival mechanism: By making fungus-eating insects “trip,” the bugs become less hungry — and less likely to feast on mushrooms.

The researchers studied a group of mushrooms that all produce psilocybin — the chemical agent that causes altered states of consciousness in human beings — but aren’t closely related. The scientists found that the clusters of genes that caused the ‘shrooms to fill themselves with psilocybin were very similar to one another, more similar even than clusters of genes found in closely related species of mushrooms.

HGT isn’t really one process, as the biologist Alita Burmeister explained in the journal Evolution, Medicine and Public Health in 2015. Instead, it’s the term for a group of more or less well-understood processes — like viruses picking up genes from one species and dropping them in another — that can cause groups of genes to jump between species.

The researchers suggested — but didn’t claim to prove — that the crisis in this case was droves of insects feasting on the defenseless mushrooms. Most of the species the scientists studied grew on animal dung and rotting wood — insect-rich environments (and environments full of opportunities to perform HGT). Psilocybin, the scientists wrote, might suppress insects’ appetites or otherwise induce the bugs to stop munching quite so much mush’.

Live Science

The Trippy Reason ‘Magic’ Mushrooms Evolved to Get You High

“Magic” mushrooms seem to have passed their genes for mind-altering substances around among distant species as a survival mechanism: By making fungus-eating insects “trip,” the bugs become less hungry — and less likely to feast on mushrooms.

The researchers studied a group of mushrooms that all produce psilocybin — the chemical agent that causes altered states of consciousness in human beings — but aren’t closely related. The scientists found that the clusters of genes that caused the ‘shrooms to fill themselves with psilocybin were very similar to one another, more similar even than clusters of genes found in closely related species of mushrooms.

That’s a sign, the researchers wrote, that the genes weren’t inherited from a common ancestor, but instead were passed directly between distant species in a phenomenon known as “horizontal gene transfer” or HGT.

However, HGT is believed to be pretty uncommon in complex, mushroom-forming fungi, turning up much more often in single-celled organisms.

When a horizontally transferred gene takes hold and spreads after landing in a new species, the paper’s authors wrote, scientists believe that’s a sign that the gene offered a solution to some crisis the organism’s old genetic code couldn’t solve on its own.

The researchers suggested — but didn’t claim to prove — that the crisis, in this case, was droves of insects feasting on the defenseless mushrooms. Most of the species the scientists studied grew on animal dung and rotting wood — insect-rich environments (and environments full of opportunities to perform HGT). Psilocybin, the scientists wrote, might suppress insects’ appetites or otherwise induce the bugs to stop munching quite so much mush’.

Live Science

The Uncertain Future Of Arecanut Market

Konkodi Padmanabha, former president of Central Arecanut and Cocoa Marketing and Processing Cooperative Ltd., said on Monday that arecanut growers need to think seriously about switching over to an alternative crop as arecanut is facing the threat of being banned.

He suggested that oil palm growers form a cooperative and create a brand for its products to capture the market.

G N Ratnakar, a leading oil palm grower from Chikkamagaluru district and a member of the government’s price fixation committee for oil palms, said now he gets an average monthly income of ₹40,000 from oil palms on his five-acre plot. Mr. Ratnakar said he also cultivated arecanut on 10 acres. He took up oil palm cultivation when the ban on gutka was looming large. He said farmers could no longer depend only on arecanut cultivation as the arecanut market is facing a number of threats.

Vasanth Bhat Todikana, an oil palm grower from near Sullia who switched to oil palm after his arecanut plantation was hit by yellow leaf disease, said region-specific cultivation technology was needed for growing oil palm.

Full article at The Hindu

Kava, The Drink Soothing The Stress of New York Millennials

It has been a mainstay in the South Pacific for thousands of years. Now, stressed-out millennial New Yorkers are kissing goodbye to alcohol and gulping down a mildly narcotic drink to ease the pain of long hours and bottleneck commutes.

Kava – a root ground to powder, mixed with water and then strained – might taste like muddy water, but it is the mood enhancer taking the edge off for those struggling to cope with hectic modern life.

Effects include a mild numbing of the tongue and lips, relaxation, and euphoria – feelings in short supply in New York.

“If any city needs to relax a little bit and calm down, slow down, it is New York,” said Mr. Harding Stowe, the 31-year-old owner of Brooklyn Kava in the neighborhood of Bushwick.

An initial kava boom in the West in the 1990s fuelled low-quality exports, which – combined with little understanding of the plant – led to health concerns and prohibitions in Europe. That led to a bust.

But while the United States Food and Drug Administration warned in 2002 of a “rare” potential risk of severe liver injury associated with kava-containing products, kava is now seeing another boom, and exports from Fiji alone more than doubled from 2012 to 2016.

Read the full article in The New Paper

Province of Ontario Demands To Halt Weed Store Placement

During a special meeting of council on Dec. 15 ahead of the presentation of the city’s 2018 operating budget, the mayor delivered a motion that requests the province back off on naming certain cities as potential homes for these LCBO-like, weed selling stores before the municipalities themselves have had the opportunity to consult with their residents and figure out proper zoning for these stores.

As the province has previously shared, the sale of the drug will be done through a storage system similar to and managed by, the LCBO. As of now, the province’s booze distributor is in the process of meeting with municipalities that have been identified to be future homes for these cannabis stores.

According to Mayor Henry, he met with officials from the LCBO, Municipal Affairs, and the Attorney General’s Office ahead of the regional council meeting on Dec. 13 to discuss the potential location, along with other questions the city has raised pertaining to the issue of legalization.

The Oshawa mayor has also previously raised concerns about the impacts on people’s health and wellbeing who live in apartments with shared ventilation systems, or how people smoking weed in their backyards will impact those around them who may choose not to smoke.

“There are far too many unanswered questions,” said Councillor Nester Pidwerbecki. “We need a lot of these questions that are asked in this motion to be answered before we can move forward.”

Read the full article at The Oshawa Express

Study: Magic Mushrooms ‘Reboot’ Brain In Depressed People

Magic mushrooms may effectively “reset” the activity of key brain circuits known to play a role in depression, the latest study to highlight the therapeutic benefits of psychedelics suggests.

A neuroscientist explains: the need for ‘empathetic citizens’ – podcast
Psychedelics have shown promising results in the treatment of depression and addictions in a number of clinical trials over the last decade. Imperial College London researchers used psilocybin – the psychoactive compound that occurs naturally in magic mushrooms – to treat a small number of patients with depression, monitoring their brain function, before and after.

“Psilocybin may be giving these individuals the temporary ‘kick start’ they need to break out of their depressive states and these imaging results do tentatively support a ‘reset’ analogy. Similar brain effects to these have been seen with electroconvulsive therapy.”

For the study, published in Scientific Reports on Friday, 20 patients with treatment-resistant depression were given two doses of psilocybin (10 mg and 25 mg), with the second dose a week after the first. Of these, 19 underwent initial brain imaging and then the second scan one day after the high dose treatment. The team used two main brain imaging methods to measure changes in blood flow and the crosstalk between brain regions, with patients reporting their depressive symptoms through completing clinical questionnaires.

The authors believe the findings provide a new window into what happens in the brains of people after they have ‘come down’ from a psychedelic, with an initial disintegration of brain networks during the drug ‘trip’ followed by a re-integration afterward.

Full article at The Guardian